Global Mycobacterium Tuberculosis Infections Pipeline Review
M2 - Tue Apr 15, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3zqhd/mycobacterium) has announced the addition of the "Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mycobacterium Tuberculosis Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mycobacterium Tuberculosis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Mycobacterium Tuberculosis Infections - Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Novartis AG - Oragenics, Inc. - Debiopharm International S.A. - Archivel Farma S.L. - Sphaera Pharma Pvt. Ltd. - Bioversys AG Drug Profiles - RUTI Vaccine - MU-1140 - MU-1140-S - (BV-6481 ethionamide) - Biotin Triazoles - Mycobacterial Gyrase Inhibitor Program - rAMtb-SIVgag Vaccine - HT-04 - NITD-349 - Small Molecules to Inhibit Structural Protein FtsZ for Bacterial Infections - Small Molecules for Bacterial and Viral Infections - Fabl Inhibitor Program - Aminopyrazinamides - MDR And XDR Tuberculosis Program - Small Molecules for Bacterial Infections - KKL-35 - R-12 - R-13 - Compound-87 - NC-00094221 - Cephalosporins For more information visit http://www.researchandmarkets.com/research/l3...obacterium
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
Oragenics to Present at Biotech Showcase 2014
Business Wire - Tue Jan 14, 7:00AM CST
Oragenics, Inc. (NYSE:MKT - OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced that Dr. John N. Bonfiglio, President and Chief Executive Officer for Oragenics, is scheduled to present at Biotech Showcase(TM) 2014, taking place January 13-15, 2014 in San Francisco, CA. Dr. Bonfiglio will present an update on Oragenics' company strategy and progress on Wednesday, January 15, 2014 at 3:00 p.m. PST to attending investors and pharmaceutical and healthcare executives.
Oragenics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
Business Wire - Mon Jan 13, 1:42PM CST
Oragenics, Inc. (NYSE MKT:OGEN) (the "Company"
RedChip TV Debuts on Bloomberg Asia
GlobeNewswire - Thu Jan 02, 4:06PM CST
RedChip Companies, Inc. ("RedChip"
Oragenics Inc closes public offering of 4.4m common shares
M2 - Thu Nov 21, 3:10AM CST
Novel antibiotics company Oragenics Inc (NYSE MKT:OGEN) reported on Wednesday the completion of its public offering of 4,400,000 shares of its common stock.
Oragenics Announces Completion of Public Offering of Common Stock
Business Wire - Wed Nov 20, 11:22AM CST
Oragenics, Inc. (NYSE MKT: OGEN) (the "Company"
Oragenics Prices Public Offering of Common Stock
Business Wire - Fri Nov 15, 8:29AM CST
Oragenics, Inc. (NYSE MKT: OGEN) (the "Company"
Oragenics Inc intends public offering of common shares
M2 - Fri Nov 15, 3:08AM CST
Novel antibiotics company Oragenics Inc (NYSE MKT:OGEN) said on Thursday that it plans to offer and sell shares of its common stock in an underwritten public offering.
Oragenics Announces Proposed Public Offering of Common Stock
Business Wire - Thu Nov 14, 5:31PM CST
Oragenics, Inc. (NYSE MKT: OGEN) today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by Oragenics.
Market Research: Gram-Positive Bacterial Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/lxgdwn/grampositive) has announced the addition of the "Gram-Positive Bacterial Infections - Pipeline Review, H2 2013" report to their offering. 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Scope - A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections. - A review of the Gram-Positive Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gram-Positive Bacterial Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Rib-X Pharmaceuticals, Inc. Aphios Corporation BioMarin Pharmaceutical Inc. Alchemia Limited Immtech Pharmaceuticals, Inc. Basilea Pharmaceutica Ltd. Oragenics, Inc. Dongwha Pharm Co., Ltd. Theravance, Inc. Phynova Group Ltd Novabiotics Ltd Priaxon AG ConjuGon, Inc. MicuRx Pharmaceuticals, Inc. AiCuris GmbH & Co. KG Destiny Pharma Ltd. Atox Bio Inc. Microbiotix, Inc. Cellceutix Corporation KYORIN Pharmaceutical Co., Ltd. Lytix Biopharma AS TAXIS Pharmaceuticals, Inc. Aureogen Biosciences, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/lx...ampositive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Oragenics Announces Breakthrough Antibiotic Analog Generation in Intrexon Collaboration
Business Wire - Thu Oct 31, 1:42PM CDT
--Engineers Genetically-Modified Host to generate Mutacin 1140 Analog(s)
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGEN)
WorldStockWire - Thu Sep 05, 4:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGENI)
WorldStockWire - Thu Sep 05, 4:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Business Wire - Mon Aug 26, 6:45AM CDT
Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a synthetic biology company, preliminary experiments demonstrate that a genetically-modified (GM) host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.
Intrexon IPO Prices High After Upsizing; Stock Soars
at Investor's Business Daily - Thu Aug 08, 11:28AM CDT
Synthetic-biology startup Intrexon (XON) soared more than 40% on the stock market Thursday after pricing its fattened IPO at the high end of its range. Intrexon priced 10 million shares at $16 apiece to raise $160 million, after last month announcing...
Enterococcus Faecium Infections - Pipeline Review, H2 2012
M2 - Thu Aug 01, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k929nz/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. I also provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Enterococcus Faecium Infections Overview Therapeutics Development An Overview of Pipeline Products for Enterococcus Faecium Infections Companies Involved in Enterococcus Faecium Infections Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Aquapharm Biodiscovery Limited - Ceragenix Pharmaceuticals - Immtech Pharmaceuticals - Lorus Therapeutics - MerLion Pharmaceuticals - MicuRx Pharmaceuticals, Inc - Nabi Biopharmaceuticals - Oragenics, Inc - Paratek Pharmaceuticals - Piramal Healthcare Limited - Trius Therapeutics, Inc - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/k9...terococcus
Oragenics to Join the Russell Microcap(R) Index
Business Wire - Tue Jun 25, 8:31AM CDT
Oragenics, Inc. (NYSE MKT:OGEN), a healthcare company focused on becoming the world leader in novel antibiotics against infectious disease and probiotcs for oral health, announced today that it will be included in the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 28, 2013, according to a preliminary list of additions posted June 21st on www.russell.com/indexes.